tiprankstipranks
Trending News
More News >

Disc Medicine assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Disc Medicine (IRON) with an Overweight rating and $85 price target The near-term focus is on bitopertin with the new drug application submission under the accelerated approval pathway in 2H25 and DISC-0974 data expected in December, the analyst tells investors in a research note. The firm models a 2026 launch for bitopertin and $1.3B in unadjusted U.S. peak sales for bitopertin.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1